{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidlpjkkpzxbhj4idviik7ilasmwdrrbslgmrc2vwah46fc6dvobm4",
    "uri": "at://did:plc:amgpmo7quvdl4rzvmmjibtx6/app.bsky.feed.post/3mkzzcocw3z72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreias53qkypc6vyotgeomjk4sv6ekx7yorv5m2rsxmp6tyyedq5tcme"
    },
    "mimeType": "image/jpeg",
    "size": 427868
  },
  "path": "/2026/05/04/us/politics/supreme-court-abortion-pill.html",
  "publishedAt": "2026-05-04T15:30:01.000Z",
  "site": "https://www.nytimes.com",
  "tags": [
    "Regulation and Deregulation of Industry",
    "Abortion",
    "Decisions and Verdicts",
    "United States Politics and Government",
    "Abortion Drugs",
    "Federal-State Relations (US)",
    "Danco Laboratories",
    "Food and Drug Administration",
    "GenBioPro Inc",
    "Supreme Court (US)",
    "Alito, Samuel A Jr",
    "Trump, Donald J"
  ],
  "textContent": "A lower-court ruling had reinstated a Food and Drug Administration requirement that patients visit a health care provider in person to obtain mifepristone.",
  "title": "Supreme Court Temporarily Restores Access to Abortion Pill by Mail"
}